← FDA DRUG APPROVALS

FDA ANDA · ANDA064097

DOXORUBICIN HYDROCHLORIDE

Sponsor: HIKMA

APPLICATION
ANDA064097
TYPE
ANDA
ORIGINAL APPROVAL
1994-09-13
LATEST ACTION
2012-07-25
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DOXORUBICIN HYDROCHLORIDEPrescription
DOXORUBICIN HYDROCHLORIDE 200MG/100ML · INJECTABLE · INJECTION

Approval history

2012-07-25Labeling · Supplement 16 · standardLabelAP
2010-11-18Labeling · Supplement 15AP
2007-02-14Labeling · Supplement 14AP
2003-07-28Labeling · Supplement 9AP
2000-09-19Labeling · Supplement 7AP
1999-08-24Labeling · Supplement 6AP
1998-12-01Labeling · Supplement 5AP
1997-05-23Manufacturing (CMC) · Supplement 2AP
1997-04-30Labeling · Supplement 4AP
1996-07-29Labeling · Supplement 1AP
1994-09-13OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →